8 analysts give Spruce Biosciences a consensus "Hold" rating, and its Q2 EPS was -$0.22, beating estimates.
8 analysts covering Spruce Biosciences, a biopharmaceutical firm focused on rare endocrine disorders, have given it a consensus "Hold" rating, with 6 analysts assigning a hold and 2 assigning a buy. The average 1-year price target is $5.00. Q2 earnings per share were -$0.22, beating estimates of -$0.32. The company is developing a non-steroidal therapy for congenital adrenal hyperplasia in Phase 2b clinical trials.
August 23, 2024
4 Articles